Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study

Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed with prostate cancer between 1990 and 1996 and treated conservatively. Ki-67 expression was assessed immunohistochemically, in two laboratories, by two different scoring methods and the results compared with cancer-specific and overall survival. The power of the biomarker was compared with Gleason score and initial serum prostate-specific antigen (PSA). Both methods showed that Ki-67 provided additional prognostic information beyond that available from Gleason score and PSA: for the semi-quantitative method, Δχ2 (1 d.f.)=24.6 (P<0.0001), overall survival χ2=20.5 (P<0.0001), and for the quantitative method, Δχ2 (1 d.f.)=15.1 (P=0.0001), overall survival χ2=10.85 (P=0.001). Ki-67 is a powerful biomarker in localised prostate cancer and adds to a model predicting the need for radical or conservative therapy. As it is already in widespread use in routine pathology, it is confirmed as the most promising biomarker to be applied into routine practice.

• Publication year

  2009

• Venue

  British Journal of Cancer

• Publication date

  2009-03-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.bjc.6604951PMID 19293807PMCID 2661778
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biological aggressiveness of prostate cancer in the Finnish screening trial

  2009cited by this paper
• Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

  2008cited by this paper
• Nomogram incorporating PSA level to predict cancer‐specific survival for men with clinically localized prostate cancer managed without curative intent

  2008cited by this paper
• Complex patterns of ETS gene alteration arise during cancer development in the human prostate

  2008cited by this paper
• Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group.

  2008cited by this paper
• A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival

  2006cited by this paper
• Long-term outcome among men with conservatively treated localised prostate cancer

  2006cited by this paper
• Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population.

  2005cited by this paper
• 20-year outcomes following conservative management of clinically localized prostate cancer.

  2005cited by this paper
• Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time

  2005cited by this paper
• Ki-67 Staining Index Predicts Distant Metastasis and Survival in Locally Advanced Prostate Cancer Treated With Radiotherapy

  2004influential reference
• Utilidad de la expresión de ki67 en las biopsias preoperatorias para predecir la recidiva bioquímica del cáncer de próstata después de la prostatectomía radical

  2004cited by this paper
• Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

  2004influential reference
• [The usefulness of Ki67 expression in the biopsy specimens, to predict the biochemical progresion of the prostate cancer after radical prostatectomy].

  2004cited by this paper
• Prostate Cancer Incidence and Mortality Rates and Trends in the United States and Canada

  2004cited by this paper
• Radical radiotherapy for prostate cancer.

  2003cited by this paper
• Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.

  2002cited by this paper
• Expresión de p53 y ki67 en piezas de prostatectomía radical. relación con los datos clínico-patológicos y supervivencia

  2000cited by this paper
• [p53 and Ki67 expression in specimens of radical prostatectomy. Relationship with clinico-pathologic data and survival].

  2000cited by this paper
• Angiogenesis, p53, bcl-2 and Ki-67 in the Progression of Prostate Cancer after Radical Prostatectomy

  1999cited by this paper
• Apoptosis, Mitosis, p53, bcl2, Ki-67 and Clinical Outcome in Prostate Carcinoma Treated by Androgen Ablation

  1999cited by this paper
• Ki-67 expression in early prostate cancer and associated pathological lesions.

  1996cited by this paper
• Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.

  1996cited by this paper
• Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma.

  1993cited by this paper
• Application of the Monoclonal Antibody Ki-67 on Prostate Biopsies to Assess the Proliferative Cell Fraction of Human Prostatic Carcinoma

  1991cited by this paper
• Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the fraction of human prostatic carcinoma.

  1991influential reference
• Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.

  1991cited by this paper
• [Use of the monoclonal antibody KI-67 in the study of the proliferative activity of urologic tumors. Preliminary data].

  1987cited by this paper
• Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation

  1983cited by this paper

• Prognostic Significance of Ki67 Expression in Prostate Cancer in Nigerians: A Single-Center Study

  2025cites this paper
• Characteristics and Prognostic Markers of Aggressive Subtypes of Thyroid Cancer: A Retrospective Study

  2025cites this paper
• Synergistic effects of HO-1 inhibition and chemotherapy on tumor proliferation and immune infiltration: An in vitro and in vivo approach to enhancing prostate cancer treatment

  2025cites this paper
• Combined MYC Activation and PTEN Loss Drives Molecular Features of Aggressive Preinvasive Lesions in Mouse Prostate.

  2025cites this paper
• Low Ki-67 labeling index is a clinically useful predictive factor for recurrence-free survival in patients with papillary thyroid carcinoma

  2025cites this paper
• Spatial metabolomics strategy reveals heterogeneity of prostate cancer based on multi-platform imaging and laser microdissection-gas chromatography-tandem mass spectrometry.

  2025cites this paper
• Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.

  2025cites this paper
• Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts

  2024cites this paper
• Neoadjuvant Exercise Therapy in Patients With Prostate Cancer.

  2024cites this paper
• Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.

  2024cites this paper
• Contemporary Strategies for Clinical Chemoprevention of Localized Prostate Cancer

  2024cites this paper
• Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized ControlledTrial.

  2024cites this paper
• Assessment of Ki-67 expression in cases of prostatic carcinoma and its correlation with clinical outcomes.

  2024cites this paper
• MRI Radiomics-Based Machine Learning Models for Ki67 Expression and Gleason Grade Group Prediction in Prostate Cancer

  2023cites this paper
• Digital analysis of the prostate tumor microenvironment with high-order chromogenic multiplexing

  2023cites this paper
• Automated Ki‐67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry

  2023cites this paper
• Prediction of disease progression indicators in prostate cancer patients receiving HDR-brachytherapy using Raman spectroscopy and semi-supervised learning: a pilot study

  2022cites this paper
• Relationship between the Expression of BRAF V600E and Ki-67 with the Recurrence of Well-Differentiated Thyroid Cancer

  2022cites this paper
• The Clinical Significance of Lymph Node Ratio and Ki-67 Expression in Papillary Thyroid Cancer

  2021cites this paper
• Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies

  2021cites this paper
• Androgen Receptor-Mediated Nuclear Transport of NRDP1 in Prostate Cancer Cells Is Associated with Worse Patient Outcomes

  2021cites this paper
• Molecular tracing of prostate cancer lethality

  2020cites this paper
• A modern era of personalized medicine in the diagnosis, prognosis, and treatment of prostate cancer

  2020cites this paper
• Targeting the splice factor kinase CLK1 in prostate cancer cells

  2020cites this paper
• Expression of Ki-67 in Prostate cancers and its correlation with Histopathological Grade and serum Prostate-specific antigen (PSA) levels: A study from eastern part of Uttar Pradesh

  2020cites this paper
• Primary large cell prostate neuroendocrine carcinoma with central and nephrogenic diabetes insipidus

  2020influential citation
• Ranking Series of Cancer-Related Gene Expression Data by Means of the Superposing Significant Interaction Rules Method

  2020cites this paper
• Translational AI and Deep Learning in Diagnostic Pathology

  2019cites this paper
• Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments

  2019cites this paper
• Inverse correlation between Ki67 expression as a continuous variable and outcomes in luminal HER2-negative breast cancer

  2019cites this paper
• Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome

  2019cites this paper
• Prostate cancer: updates on current strategies for screening, diagnosis and clinical implications of treatment modalities

  2018cites this paper
• The clinicopathological significance of Ki67 in papillary thyroid carcinoma: a suitable indicator?

  2018cites this paper
• IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.

  2018cites this paper
• Higher Ki67 expression in fibroblast like cells at invasive front indicates better clinical outcomes in oral squamous cell carcinoma patients

  2018cites this paper
• 20(S)-protopanaxadiol regio-selectively targets androgen receptor: anticancer effects in castration-resistant prostate tumors

  2018cites this paper
• Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study.

  2018cites this paper
• Prostate Cancer Disparities by Race and Ethnicity: From Nucleotide to Neighborhood.

  2018cites this paper
• Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men

  2018cites this paper
• Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer.

  2017cites this paper
• Evaluating synergy between deregulation of the Wnt, PI3-Kinase and MAP-Kinase pathways in prostate tumourigenesis

  2017cites this paper
• Immunohistochemical analysis of XRCC5, MDH2 and ACO2 in prostate cancer

  2017cites this paper
• Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography.

  2017cites this paper
• High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.

  2017cites this paper
• Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy.

  2017cites this paper
• IMMUNOHISTOCHEMICAL EXPRESSION OF CYCLIN D1 AND KI 67 IN PREMALIGNANT AND MALIGNANT PROSTATIC LESIONS.

  2017cites this paper
• Prognostic role of Ki-67 score in localized prostate cancer: A systematic review and meta-analysis.

  2017cites this paper
• Comparison of SKIP expression in malignant pleural mesotheliomas with Ki-67 proliferation index and prognostic parameters.

  2016cites this paper
• Prognostic Factors of Prostate Cancer in Tunisian Men: Immunohistochemical Study.

  2016cites this paper
• The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients

  2016cites this paper
• Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies

  2016cites this paper
• KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer–a targeted molecular approach

  2016cites this paper
• 4-Methoxydalbergione suppresses growth and induces apoptosis in human osteosarcoma cells in vitro and in vivo xenograft model through down-regulation of the JAK2/STAT3 pathway

  2016cites this paper
• Survival predictors in patients with prostate adenocarcinoma with hormonal blockade.

  2016cites this paper
• Ki67 as a prognostic marker in comparison with Gleason's grading system in prostatic carcinoma

  2016cites this paper
• Does the molecular classification of breast cancer point the way for biomarker identification in prostate cancer

  2016cites this paper
• Nomination and validation of the long noncoding RNA SChLAP1 as a risk factor for metastatic prostate cancer progression: a multi-institutional high-throughput analysis

  2015cites this paper
• ability of PITX2 methylation to predict survival in patients with prostate cancer

  2015cites this paper
• Evaluation of an Epithelial Plasticity (EP) Biomarker Panel in Men with Localized Prostate Cancer

  2015cites this paper
• Expression of Estrogen Receptor β and Ki 67 in Benign & Malignant Human Prostate Lesions by Immunohistochemistry

  2015cites this paper
• Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy

  2015cites this paper
• Prognostic classification of thyroid follicular cell tumors using Ki-67 labeling index: risk stratification of thyroid follicular cell carcinomas.

  2015cites this paper
• Image analysis of prostate cancer tissue biomarkers

  2015cites this paper
• A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.

  2015cites this paper
• Epigenetic Analysis of the Kallikrein Gene Family and Associated Pathways as a Novel Panel of Prostate Cancer Biomarkers

  2015cites this paper
• EN2 in Prostate Cancer.

  2015cites this paper
• [Role of tissue markers on diagnosis, prognosis and monitoring of prostate cancer].

  2015cites this paper
• Role of ERG, PTEN and KI67 Proteins Expression in Prognosis of Metastatic Prostate Cancer

  2015cites this paper
• Proteomic Identification and Systematic Verification of Biomarkers for Aggressive Prostate Cancer

  2015cites this paper
• Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer

  2015cites this paper
• Evaluation of the Current Situation Tissue and Serum Biomarkers in Prostate Cancer

  2015cites this paper
• Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.

  2015cites this paper
• Renal Cancer Resistance to VEGF Receptor Tyrosine Kinase Inhibitors.

  2015cites this paper
• Exploring mechanisms of prostate tumourigenesis in mouse models

  2015cites this paper
• Ability of PITX2 methylation to predict survival in patients with prostate cancer

  2015cites this paper
• Cancer diagnostic classifiers based on quantitative DNA methylation

  2014cites this paper
• Proliferation index revisited in neuroblastic tumors.

  2014cites this paper
• DNA methylation gene-based models indicating independent poor outcome in prostate cancer

  2014cites this paper
• Molecular markers to guide primary radical treatment selection in localized prostate cancer

  2014cites this paper
• Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.

  2014cites this paper
• A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis

  2014cites this paper
• Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer

  2014cites this paper
• Immunohistochemical profile of ductal adenocarcinoma of the prostate

  2014cites this paper
• Prevention and early detection of prostate cancer.

  2014cites this paper
• DNA methylation of PITX2 predicts poor survival in men with prostate cancer.

  2014cites this paper
• Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer

  2014cites this paper
• Prognostic value of a cell cycle progression score for men with prostate cancer.

  2014cites this paper
• RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.

  2014cites this paper
• Hypoxia in prostate cancer: Gene expression profiling in relation to disease aggressiveness and treatment interventions

  2014cites this paper
• Markers in Prostate Cancer

  2014cites this paper
• Androgen receptor phosphorylation in prostate diseases

  2014influential citation
• Prevention and early detection of prostate cancer

  2014cites this paper
• EN2: a novel prostate cancer biomarker.

  2013cites this paper
• Ki 67-BCL 2 index in prognosis of malignant peritoneal mesothelioma

  2013cites this paper
• Novel Biomarkers in Prostate Cancer and Phi Score

  2013cites this paper
• PROGNOSTIC SIGNIFICANCE OF MIB-1 ( Ki-67 ) EXPRESSION IN PROSTATE CANCER AND MATCHED LYMPH NODE METASTASES

  2013cites this paper
• Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma.

  2013cites this paper
• Quantifying the ki-67 heterogeneity profile in prostate cancer.

  2013cites this paper
• Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08.

  2013cites this paper
• Prostate needle biopsy: what we do and what should be improved.

  2013cites this paper